

*Research Article***The role of neutrophil gelatinase-associated lipocalin (NGAL) in predicting acute kidney injury after cardiac surgery**

**Maha F. Sawi Elgarhy, Ahmad A. Omran,
Hanan M. Kamel and Manal M. Saber**

Department of Clinical Pathology, Minia University

Abstract

Cardiac surgery-associated acute kidney injury (CSA-AKI) is a common and serious postoperative complication of cardiac surgery. Acute kidney injury (AKI) is defined as increase in SCr by > 0.3 mg/dl ($> 26.8 \mu\text{mol/l}$) within 48 hours; or increase in SCr to > 1.5 times baseline, which is known or presumed to have occurred within the prior 7 days; or urine volume < 0.5 ml/kg/h for 7 hours. Since the early stages of AKI are often reversible, AKI should be prevented and/or treated by various approaches instituted as early as possible after the initiating insult, well before serum creatinine even begins to rise. There are promising candidate biomarkers with the ability to detect an early AKI; Neutrophil gelatinase-associated lipocalin (NGAL) is one of such biomarkers. **The aim of this work** is to assess the role of serum NGAL as early biomarker for prediction of acute kidney injury, before the rise in serum creatinine, following cardiac surgery.

The study was conducted on 70 patients selected from patients who were subjected to cardiac surgery at Cardio-Thoracic Surgical Department of Minia University Hospital and proved that they developed AKI after the surgery. The study also included 10 apparently healthy volunteers who served as a control group of matched age and sex. Serum NGAL by ELISA was measured to patients group (group I) on 1st day post operative (7 hours after discharge from surgical room), 2nd day and 3rd day with 24 hours interval and applied also to subjects of control group (group II). The ROC analysis has been extensively used as a fundamental evaluation tool. It showed that serum NGAL of patients group on **1st day and 2nd day** post operative was a **good marker** for prediction of AKI, Concerning **3rd day** post operative it showed that NGAL was an **excellent marker** for prediction of AKI. Conclusions: Serum NGAL was early biomarkers of AKI prior to rise in serum creatinine and has high positive predictive values for occurrence of AKI following cardiac surgery.

Key Words:

kidney injury, Neutrophil gelatinase, lipocalin, Cardiac surgery

Introduction

Acute Kidney injury (AKI) is one of a number of conditions that affect kidney structure and function. It is defined by an abrupt decrease in kidney function that includes, but is not limited to, acute renal failure (ARF) (Hoste et al., 2006 and Uchino et al., 2006).

AKI is defined as any of the following (Not Graded): Increase in serum creatinine by > 0.3 mg/dl ($> 26.8 \mu\text{mol/l}$) within 48 hours; or Increase in SCr to > 1.5 times baseline, which is known or presumed to have occurred

within the prior 7 days; or urine volume < 0.5 ml/kg/h for 7 hours (Bellomo et al., 2004 and Mehta et al., 2007).

To create uniformity in the diagnosis of AKI, the RIFLE (risk of renal injury/injury to the kidney/failure of kidney function/loss of kidney function/end-stage disease) criteria were proposed in 2004 (Bellomo et al., 2004), followed by the Acute Kidney Injury Network (AKIN) criteria in 2007 (Mehta et al., 2007) and the Kidney Disease-Improving Global Outcomes (KDIGO) criteria in 2012 (Kidney International KDIGO 2012). These

criteria express the deterioration of kidney function as a decline in the estimated glomerular filtration rate (eGFR), which is based on an increasing serum creatinine (SCr) concentration and a declining urine output (de Gues et al., 2016).

AKI is a broad clinical syndrome encompassing various etiologies, including specific kidney diseases (e.g., acute interstitial nephritis, acute glomerular and vasculitic renal diseases); non-specific conditions (e.g., ischemia, toxic injury); as well as extrarenal pathology (e.g., prerenal azotemia, and acute postrenal obstructive nephropathy) (Bellomo et al., 2008 and Gaffney et al., 2010).

Worldwide, more than 2 million cardiac surgeries are performed each year. Cardiac surgery-associated acute kidney injury (CSA-AKI) is a serious postoperative complication, and is the second most common cause of AKI in the intensive care unit (Uchino et al., 2005).

An incidence of CSA-AKI of up to 39% has been reported, varying depending on patient-related baseline characteristics and the type of surgery (Mao et al., 2013). Between 3% and 6.5% of all surgical patients require renal replacement therapy. This worst stage of CSA-AKI is independently associated with a very high mortality rate (Wald et al., 2010).

Other clinical consequences of CSA-AKI are increased length of hospital stay, increased risk of chronic kidney disease (CKD), and increased risk of death within 5 years after surgery (Hansen et al., 2013).

The success of interventions or new therapeutic strategies aimed at reducing the incidence of CSA-AKI and its related outcomes depends on the optimum time of their application, which is at the very early stages of AKI (de Gues et al., 2016).

However, in health, the kidneys have a significant degree of excess capacity, such that 50% of the functional kidney mass can be

damaged without any drop in SCr-based eGFR. Therefore, an increase in SCr occurs relatively late after the initial injurious event (24-48 hours), with hemodilution related to pump priming as an additional contributor to this delay (Perrone et al., 1992 and Coca et al., 2008). The field of AKI biomarkers is rapidly evolving, and new proteins released by injured tubular cells are constantly being discovered. All of these new biomarkers carry the potential to serve as markers for acute tubular damage in the absence of functional AKI (Devarajan et al., 2008). Most promising candidate is neutrophil gelatinase-associated lipocalin (NGAL).

NGAL: Neutrophil gelatinase-associated lipocalin (NGAL) is 20 kDa iron-transporting glycoprotein which accumulates in the kidney tubules and urine after nephrotoxic and ischemic insults (Mishra et al., 2003). Human NGAL was originally isolated from the supernatant of activated neutrophils. It has been proposed as an early, sensitive, noninvasive biomarker for AKI (Sargentini et al., 2012).

NGAL is a small siderophoric protein that is intensely up-regulated and excreted in cases of acute tubular damage. It can be detected in both plasma and urine (Mishra et al., 2004).

In the early phases of AKI, NGAL mitigates iron-mediated toxicity by providing a reservoir for excess iron, and in subsequent phases, it promotes regeneration and repair by regulating intracellular iron availability (Mishra et al., 2006).

NGAL is readily filtered in the glomerulus and readily reabsorbed in the proximal tubular segments (Mori et al., 2000). Immediately following diverse injurious events, NGAL is up-regulated in the distal parts of the nephron (Devarajan 2007).

Subjects and Methods

The study was conducted on 20 patients selected from patients who were subjected to cardiac surgery at Cardio-Thoracic Surgical

Department of Minia University Hospital, through the period from September, 2012 to June, 2016 and proved that they developed AKI after the surgery as manifested by an absolute increase in serum creatinine of ≥ 0.5 mg/dl or more, equivalent to a percentage increase in serum creatinine $\geq 25\%$ or more (1.25 -fold from base line) within 48 hours according to RIFLE and AKIN criteria. The study also included 10 apparently healthy volunteers who served as a control group of matched age and sex.

Excluded from the study were patients on nephrotoxic drugs. Exclusion criteria: those with pre-existing renal insufficiency, Patients on immunosuppressive therapy and/or patients with active infection at time of study.

All the study individuals were subjected to: Thorough clinical history, Clinical examination, routine Laboratory investigations and special Laboratory investigations: Serum NGAL by ELISA which applied to patients of group I on 1st day post operative (6 hours after discharge from surgical room), 7nd day and 14th day with 48 hours interval and applied also to subjects of control group (group II).

Statistical analysis

All analyses were performed with version 19 of Statistical Package of Social Science (SPSS). Qualitative data were expressed as proportions, while quantitative data were expressed as mean \pm standard deviation (SD). Qualitative data were analyzed by Chi square (χ^2) test. Comparisons between groups for

normally distributed quantitative data were performed by Student's t-test. Correlations between variables were obtained by Pearson's test.

For all analysis, statistical significance was defined as p value less than 0.05.

The ROC analysis has been extensively used as a fundamental evaluation tool in clinical studies pertaining to diagnostic testing. A ROC curve is a graphical plot of the sensitivity on the y-axis versus (1-specificity) on the x-axis for a binary classifier system as its discrimination threshold is varied. For biomarker analysis, the binary classification task is typically to determine whether a subject has a certain disease (such as AKI) or not. Characteristically, ROC curves are generated for various cut-off points for the biomarker concentration under consideration. A commonly derived statistic from the ROC curve is the area under the curve (AUC). An AUC of 1.0 represents a perfect biomarker, whereas an AUC of 0.5 indicates a result that is no better than expected by random chance. An AUC of ≥ 0.75 or above is generally considered a good biomarker, and an AUC of ≥ 0.9 or above would represent an excellent biomarker (Zou et al., 2007).

Results

The study showed that there was significant increase of serum NGAL in patients group on 1st day, 7nd day and 14th day following the cardiac surgery when compared with control group as shown in table (1).

Table (1): Results of serum NGAL

Variable	Group I (n=20)	Group II (n=10)	P - value
NGAL 1 st day µg/dl			
Range	0.03 – 3.6	0.1 – 0.90	
Mean±SD	1.39±1.14	0.31±0.26	P=0.0003
NGAL 2 nd day			
Range	0.06 – 6.0	0.1 – 0.90	
Mean±SD	1.68±1.76	0.31±0.26	P=0.002
NGAL 3 rd day			
Range	0.2 – 4.2	0.1 – 0.90	
Mean±SD	1.70±1.16	0.31±0.26	P=0.000

As demonstrated in figures 1, 2 and 3, Roc curves showed an AUC of 0.84 (p<0.0001), an AUC of 0.80 (p<0.002) and an AUC of 0.90 (p<0.0001) for 1st day, 2nd day and 3rd day post operative respectively.




Figure (1): ROCcurve of NGAL on 1st day




Figure (1): ROCcurve of NGAL on 2nd day




Figure (2): ROCcurve of NGAL on 3rd day

In the study, serum NGAL showed significant positive correlation with creatinine on 1st day post operative ($r=0.56$; $p=0.004$), 2nd day ($r=0.74$; $p=0.0006$) and 3rd day ($r=0.50$; $p=0.004$).

Discussion

In this study serum NGAL had been found that there was significant increase in serum NGAL in patients group on 1st day, 2nd day and 3rd day post operative than control group. Using ROC curve analysis, Our study showed that serum NGAL considered a good marker for prediction of AKI at 1st day (6 hours post operative) and 2nd day. An excellent marker at 3rd day following cardiac surgery

These findings were in agreement with other studies; Jain et al., (2016) were able to verify the role of urinary NGAL as an early biomarker of AKI in off pump coronary bypass surgery.

Perhaps the strongest evidence supporting the role of NGAL as an early biomarker for AKI in cardiac surgery patients, came from the meta analysis conducted by Zhou et al., (2016) Neutrophil gelatinase-associated lipocalin (NGAL) has been identified as one of the most sensitive and specific biomarkers for predicting cardiac surgery-associated acute kidney injury (CSA-AKI).

Moreover in another study conducted by deGues et al., (2016) they also were able to document the role of NGAL in early diagnosis of CSA-AKI.

Moreover Bennett et al., (2008) in a prospective uncontrolled cohort study concluded that NGAL predicts AKI, mortality and morbidity after pediatric cardiac surgery. Several other studies have reported NGAL as a sensitive and specific predictor of AKI after cardiac surgery (Krawczeski et al., 2011 and Mishra et al., 2005).

Conclusions

According to the study, serum NGAL is an early biomarker of AKI prior to rise in serum creatinine, and showed a high positive predictive values for occurrence of AKI following cardiac surgery. Accordingly it can be used for early detection of AKI.

References

1. Bellomo R, Kellum J and Ronco C (2004): "Defining acute renal failure: physiological principles." *Intensive care medicine*; 39(1): 33-37.
2. Bellomo R, Auriemma S, Fabbri A, D'onofrio A, Katz N, McCullough P, Ricci Z, Shaw A and Ronco C (2008): "The pathophysiology of cardiac surgery-associated acute kidney injury (CSA-AKI)." *The International journal of artificial organs*; 31(2): 166-78.
3. Bennett M, Dent CL, Ma Q, Dastrala S, Grenier F, Workman R, Syed H, Ali S, Barasch J and Devarajan P (2008): "Urine NGAL predicts severity of acute kidney injury after cardiac surgery: a prospective study." *Clinical Journal-American Society Of Nephrology*; 3(3): 770.
4. Coca S, Yalavarthy R, Concato J and Parikh C(2008): "Biomarkers for the diagnosis and risk stratification of acute kidney injury: a systematic review." *Kidney international*; 73(9): 1008-16.
5. de Geus HR, Ronco C, Haase M, Jacob L, Lewington A and Vincent JL (2016): The cardiac surgery-associated neutrophil gelatinase-associated lipocalin (CSA-NGAL) score: A potential tool to monitor acute tubular damage, *J Thorac Cardiovasc surg.*; (16): S 0222-0223.
6. Devarajan P (2007): Proteomics for biomarker discovery in acute kidney injury. *Seminars in nephrology*; 27(6): 737-51.
7. Devarajan P (2008): "Emerging urinary biomarkers in the diagnosis of acute kidney injury." *Expert opinion on medical diagnostics*; 2(4): 387-98.
8. Gaffney AM and Sladen RN (2010): "Acute kidney injury in cardiac surgery." *Current Opinion in Anesthesiology*; 24(1): 00-9.
9. Hansen MK, Gammelager H, Mikkelsen MM, Hjortdal VE, Layton J B, Johnsen SP and Christiansen CF (2013): "Post-operative acute kidney injury and five-year risk of death, myocardial infarction,

- and stroke among elective cardiac surgical patients: a cohort study." *Critical care*; 17(6): R292.
10. Hoste EA, Clermont G, Kersten A, Venkataraman R, Angus DC, De Bacquer D and Kellum J A(2006): "RIFLE criteria for acute kidney injury are associated with hospital mortality in critically ill patients: a cohort analysis." *Critical care* ; 10(3): R73.
 11. Jain V, Mehta Y, Gupta A, Sharma R, Raizada A and Trehan N (2016): "The role of neutrophil gelatinase-associated lipocalin in predicting acute kidney injury in patients undergoing off-pump coronary artery bypass graft: A pilot study." *Annals of cardiac anaesthesia*; 1(2): 220-9.
 12. Krawczeski CD, Goldstein S L, Woo JG, Wang Y, Piyaphanee N, Ma Q, Bennett M and Devarajan P (2011): "Temporal relationship and predictive value of urinary acute kidney injury biomarkers after pediatric cardiopulmonary bypass." *Journal of the American College of Cardiology*; 58(22): 2301-9.
 13. Mao H, Katz N, Ariyanon W, Blanca-Martos L, Adybelli Z, Giuliani A, Danesi TH, Kim JC, Nayak A and Neri M (2013): "Cardiac surgery-associated acute kidney injury." *Cardiorenal medicine*; 3(3): 178-99.
 14. Mehta RL, Kellum JA, Shah SV, Molitoris BA, Ronco C, Warnock DG and Levin A(2007): "Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury." *Critical care*; 11(2): R31.
 15. Mishra J, Ma Q, Prada A, Mitsnefes M, Zahedi K, Yang J, Barasch J and Devarajan P(2003): "Identification of neutrophil gelatinase-associated lipocalin as a novel early urinary biomarker for ischemic renal injury." *Journal of the American Society of Nephrology*; 14(10): 2034-43.
 16. Mishra J, Mori K, Ma Q, Kelly C, Yang J, Mitsnefes M, Barasch J and Devarajan P (2004): "Amelioration of ischemic acute renal injury by neutrophil gelatinase-associated lipocalin." *Journal of the American Society of Nephrology*; 15(12): 3073-82.
 17. Mishra J, Dent C, Tarabishi R, Mitsnefes MM, Ma Q, Kelly C, Ruff S M, Zahedi K, Shao M and Bean J (2005): "Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery." *The Lancet*; 365(9326): 1251-8.
 18. Mishra J, Ma Q, Kelly C, Mitsnefes M, Mori K, Barasch J and Devarajan P (2006): "Kidney NGAL is a novel early marker of acute injury following transplantation." *Pediatric Nephrology*; 21(6): 806-13.
 19. Mori K, Lee HT, Rapoport D, Drexler IR, Foster K, Yang J, Schmidt-Ott KM, Chen X, Li JY and Weiss S (2005): "Endocytic delivery of lipocalin-siderophore-iron complex rescues the kidney from ischemia-reperfusion injury". *The Journal of clinical investigation*; 115(3): 610-21.
 20. Perrone RD, Madias NE and Levey AS (1992): "Serum creatinine as an index of renal function: new insights into old concepts." *Clinical chemistry*; 38(10): 1933-53.
 21. Sargentini-Maier ML, Sokalski A, Boulanger P, Jacobs T and Stockis A (2012): "Brivaracetam disposition in renal impairment." *The Journal of Clinical Pharmacology* ; 52(12): 1927-33.
 22. Uchino S, Kellum JA, Bellomo R, Doig GS, Morimatsu H, Morgera S, Schetz M, Tan I, Bouman C and Macedo E (2005): "Acute renal failure in critically ill patients: a multinational, multicenter study." *Jama*; 294(7): 813-8.
 23. Uchino S, Bellomo R, Goldsmith D, Bates S and Ronco C (2006): "An assessment of the RIFLE criteria for acute renal failure in hospitalized patients." *Critical care medicine*; 34(7): 1913-7.
 24. Wald R, Quinn RR, Luo J, Li P, Scales DC, Mamdani MM and Ray JG (2010): "Chronic dialysis and death among survivors of acute kidney injury requiring dialysis." *Jama* ; 302(11): 1179-80.

20. Zhou F, Luo Q, Wang L and Han L (2016): "Diagnostic value of neutrophil gelatinase-associated lipocalin for early diagnosis of cardiac surgery-associated acute kidney injury: a meta-analysis." *European Journal of Cardio-Thoracic Surgery*; 49(3): 446-50.
21. Zou KH, O'Malley AJ and Mauri L (2007): "Receiver-operating characteristic analysis for evaluating diagnostic tests and predictive models." *Circulation*; 115(5): 704-10.